We review our studies on how to identify the most appropriate models of diseases, and how to determine their parameters in a quantitative manner given a short time series of biomarkers, using intermittent androgen deprivation therapy of prostate cancer as an example. Recently, it has become possible to estimate the specific parameters of individual patients within a reasonable time by employing the information concerning other previous patients as a prior. We discuss the importance of using multiple mathematical methods simultaneously to achieve a solid diagnosis and prognosis in the future practice of personalized medicine.
INTRODUCTION
Developments in measurement techniques have enabled us to model diseases quantitatively and mathematically. For example, several mathematical models [1] [2] [3] [4] [5] have been proposed for intermittent androgen deprivation therapy for prostate cancer [6] [7] [8] [9] [10] . When we employ such a mathematical dynamical model in a clinical setting, there are certain problems that commonly appear, even if the target diseases are different. For example, we need to estimate a set of parameters characterizing each patient from a short time series of biomarkers [11, 12] . Further problems include how to optimize a treatment schedule given such a personalized set of parameters [13] [14] [15] .
In this review, we focus on the first problem of mathematical medicine, i.e., how to estimate a set of parameters for quantitatively characterizing each patient. Because the mathematical modeling of intermittent androgen deprivation therapy for prostate cancer with the sensitive biomarker Prostate-Specific Antigen (PSA) is well developed, we employ it as an example.
PHYSIOLOGY OF PROSTATE CANCER
Androgen deprivation therapy (ADT) is often used to treat prostate cancer. ADT suppresses the growth of prostate cancer by lowering the androgen level in patients. Although ADT often shows remarkable effects in tumor regression initially, prostate cancer acquires the ability to grow without androgen in long-term ADT treatment, resulting in eventual relapse.
Intermittent ADT [6] [7] [8] [9] [10] has been introduced in order to overcome this problem and sustain the hormonal sensitivity in prostate cancer. Intermittent ADT is an approach that is based on the premise that cycles of androgen deprivation followed by re-exposure may delay "androgen independence", reduce treatment morbidity, and improve quality of life. In intermittent ADT, patients continue ADT until the PSA levels decline sufficiently, and then cease ADT. After the PSA levels elevate again to upper threshold values, ADT is resumed. From a mathematical viewpoint, one problem concerning intermittent ADT is that the protocol of intermittent ADT is dependent on the decisions of individual medical doctors, and it is not clear whether the applied protocol is optimal or not for each patient.
In order to personalize intermittent ADT, several mathematical models of intermittent ADT have been proposed [1] [2] [3] [4] [5] . Among these models, Ideta et al. [1] were the first to mention the mathematical possibility that intermittent ADT can prevent the relapse of prostate cancer if the population of androgen independent cancer cells shrinks after the hormonal therapy is stopped. However, this model is unable to explain the bi-phasic decline of PSA in periods that the hormonal therapy is carried out. In order to describe the bi-phasic decline during on-treatment periods, Hirata et al. [3] have proposed a three-dimensional piecewise-linear model. This model describes the dynamics of prostate cancer effectively and quantitatively, and it will be introduced mathematically in the next section.
CONSIDERED MODEL
In general, a dynamical system describing disease dynamics can be written in the following form:
where x describes a state of the target disease, m corresponds to a regimen of treatment, and f m describes the dynamics of the disease given a regimen m of treatment. Such a system encompasses intermittent ADT of prostate cancer [6] [7] [8] [9] [10] . Here, we describe the model of Hirata et al. [3] . The model describes the dynamical behavior of prostate cancer, and the dynamics has been comprehensively studied [11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] . To define the model, we first define the following three variables: x 1 corresponds to the non-dimensionalized number of androgen dependent cancer cells, and x 2 and x 3 to the non-dimensionalized numbers of androgen independent cancer cells. When the hormonal therapy is active (m=1), the cancer population specified by x 1 may change to that specified by x 2 or x 3 , and the cancer population specified by x 2 may change to that specified by x 3 (see Figure 1) . When the hormonal therapy is suspended (m=0), androgen independent cells, expressed by x 2 , may change back to androgen dependent cells, expressed by x 1 . However, androgen independent cells expressed by x 3 , cannot change back to cancer population specified by either x 1 or x 2 (see Figure 1) . That is, the androgen independent cells expressed by x 2 are cells generated through reversible changes, and the androgen independent cells expressed by x 3 are cells generated through irreversible changes like mutation. Mathematically, the dynamics among these variables is written as
while the hormonal therapy is active (m = 1), and
while the hormonal therapy is inactive (m = 0). The level of PSA is now assumed to be pðtÞ=x 1 ðtÞ þ x 2 ðtÞ þ x 3 ðtÞ, for simplicity. The unit of t is one day.
In the paper of Hirata et al. [3] , a method of fitting with constraints was also proposed to achieve physiological validity of the model. In particular, the method focused on the non-negativities of x 1 , x 2 , and x 3 ; moderate amounts of changes within a day; and the reproducibility of relapse when the hormonal therapy is continued. To achieve the non-negativity of x 1 , x 2 , and x 3 , we assume that w m i, j ³0 when i≠j and m∈f0,1g. To ensure moderate amounts of changes within one day, we assume that -0:2£w m i, i £0:2, w m i, j £0:1 when i≠j, and -0:2£ P i w m i, j £0:2 for j∈ f1, 2, 3g and m∈f0,1g. For the reproducibility of relapse, we assume that w 1 3, 3 ³0, pð360Þ£2, and pð360 Â5Þ ³10, where pðtÞ is the level of PSA at time t in the case that we keep the hormonal therapy active (m=1) for all time. We use the penalty method to enforce these conditions. If we would like to realize x³0, then we minimize the following quantity hðxÞ: The function hðxÞ=0 when x³0 is satisfied. Thus, by combining this with the fitting error represented by the L 1 norm, the cost function to determine the parameters and initial conditions q=ðw, xð0ÞÞ can be written as follows:
where fðt i , o i Þji=1, 2, :::, Ig are the observed PSA values o i at t i , and
The last two terms of Equation (6) correspond to constraints realizing the assumptions that the PSA value will once go down and reach the value less than 2 ng/ml one year after the start of the hormonal therapy, while it will become greater than 10 ng/ml after 5 years if we continue the hormonal therapy. These assumptions came from general common observations made by urologists [3] . A summary of recent methods [11, 12, 17, 19, 20] for the system identification and parameter estimation is presented in Table 1 . The methods are roughly classified into three classes: parametric estimation, semi-parametric estimation, and non-parametric estimation. In the following sections, we introduce these methods one at a time.
PARAMETRIC ESTIMATION
Two parameter-estimation methods have been proposed for estimating a set of parameters for dynamical diseases. The first method is to use cross entropy [19] , and the second method is to use the Bayesian theorem with the data of past patients [12] .
The method of cross entropy [19] involves choosing a set of parameters by recursively minimizing the KullbackLeibler divergence [23] between the previous truncated distribution and the current distribution without the truncation such that the cost function is sufficiently small. The method of cross entropy can be formulated as follows. First, we define a cost function FðqÞ as
þ CðqÞ:
At each step of iteration, we randomly draw N sets of parameters q 1 , q 2 , …, q N such that each i th parameter value follows the Gaussian distribution with mean u Bootstrapping [17] Cross entropy [19] Variational Bayes [20] Gaussian process [20] Temporal expert advice [11] Bayes with past patients' prior [12] Parametric
Reproducibility of relapse under continuous ADT
Use of past other patients' data 
and complete a set of routines for an iteration. Here, we set α∈ð0:5, 1Þ and β∈ð0:8, 1Þ. We stop the iterations when either the cost function reaches our intended lower bound or the number of iterations reaches a certain number. This method was demonstrated by Guo et al. [19] . The parameter values can be estimated using the first two and half cycles of intermittent ADT. The prediction intervals for the PSA values were also estimated.
The second method is based on the Bayesian theorem, with a prior that is constructed based on the data of past patients [12] . Suppose that we maximize the posterior probability QðqjoÞ of a set q of parameters, given a dataset o. Using the Bayesian theorem, the posterior probability can be written as follows:
By taking the logarithm, Equation (13) can be rewritten as
where V is constant. We now model the prior distribution Q(q) by using the multivariate Gaussian distribution estimated from past patients. Letting q and W denote the mean and the covariance matrix, and enforcing the constraints of Equation (6) for the physiological appropriatenesss, the problem of estimating a set of parameters for the current patient can be written as
where is the standard deviation for the observations of the PSA values. In the paper of Hirata et al. [12] , we employed the entire datasets of 36 other patients, who were not used later in evaluating the fitting accuracy for constructing the prior distribution.
In the paper of Hirata et al. [12] , it was shown that the estimated parameter values with the first one and half cycles exhibited correlations with those obtained using the entire datasets.
SEMI-PARAMETRIC ESTIMATION
By a semi-parametric method, we mean a method that combines the parametric model described in Equations (2) and (3) with a non-parametric approach such that we can quantify the uncertainty in terms of the estimation of the parameters in Equations (2) and (3). Two methods have been proposed for estimating a set of parameters by using the semi-parametric estimation. The first method is that of bootstrapping [17] . The second method is called the temporal expert advice method [11] . The bootstrapping method [17] is quite simple, and takes into account the uncertainty owing to a few measurements of PSA.We resample a given dataset with replacements 100 times. For each resampled dataset, we obtain a set of parameters resulting from Equation (5), and represent the uncertainty as the distribution of the 100 estimated sets of parameters.The problem with the bootstrapping method is its huge computational cost.
In the temporal expert advice method [11] , we prepare experts by using the sets of parameters for past patients and fitting only the initial conditions with the data of the target patient. Then, the initial value obtained using the set of parameters for each past patient provides a prediction for the future. Thus, we use the first few time points to evaluate whether the past patients have similar dynamical disease behavior as the current patient or not. Then, depending on the similarities, we either take the weighted average over the predictions or we take an ensemble of predictions to obtain the prediction intervals. This method has been tested in Morino et al. [11] on the datasets of patients who had previously undergone the first radical treatments and were waiting for the start of their next additional treatment.
NON-PARAMETRIC ESTIMATION
There have also been two non-parametric-estimation methods proposed in the context of the mathematical modeling of prostate cancer under intermittent ADT. The first method is the variational Bayes [20] method, and the second is the Gaussian process [20] method.
In the variational Bayes method [20] , we use a piecewise affine model. Consider a phase space X that includes ð2m þ 1Þ -dimensional vectors x t =[y t -1 , y t -2 , :::, y t -m , u t , u t -1 , :::, u t -m ], where y t corresponds to the logarithm of the PSA value at time t, and u t to the treatment option at time t. Suppose that a partition X i =fz∈R 2mþ1 j H i z£K i , I i z<G i g of the phase space X is given, satisfying X =U i X i . Then, a piecewise affine model to be used in this case is defined as
for x t ∈X i . We would like to approximate y t by f ðx t Þ. We denote D=fðx t ,y t Þg. When we apply the Gaussian mixture for modeling x t , it can be written as
Where φ i denotes the weight of the i th Gaussian distribution, N represents the Gaussian distribution, and i and S 
and each y t is modeled as
Therefore, the total probability that we have data D and latent variables Z=fz n i g for the Gaussian mixture M, a model of input Ψ, and a model of output Θ, is given by
The estimates of the parameters are obtained as the mean with respect to the posterior distribution constructed by the Bayes theorem. However, the computation of the posterior is a difficult task in the Gaussian mixture model. Thus, in the variational Bayes method we approximate the posterior as a computationally tractable form and obtain the parameters M,Ψ, and Θ. This is the variational Bayes method for non-parametric estimation.
The Gaussian process method [20] can be summarized as follows. Suppose that e f ðxÞ obeys the zero-mean Gaussian distribution. That is, for any finite input points ðx 1 , x 2 , :::, x k Þ, the joint distribution of ð e f ðx 1 Þ, e f ðx 2 Þ,:::, e f ðx k ÞÞ is zero-mean multivariate Gaussian. Then, we can define a covariance function as
where E e f~GP represents the operation of taking the expectation in terms of the Gaussian process e f . Let f =[ e f ðx 1 Þ, e f ðx 2 Þ, :::, e f ðx n Þ] T , and f Ã = e f ðxÞ. Then, we
where we define
K 12 =[kðx 1 , xÞ, kðx 2 , xÞ, :::, kðx n , xÞ] T ,
and
We employ the distribution introduced above as a prior
We also model the likelihood of f as a Gaussian distribution, as follows:
Because the posterior distribution of f Ã also follows the Gaussian distribution, the mean
Writing the mean in a different way, we have
where α=ðK 11 þ 2 IÞ -1 y. The variance of f Ã is given by
Suzuki and Aihara [20] discussed the fact that the variational Bayes method is slightly more effective for the long-term predictions, while the Gaussian process is better for short-term predictions.
DISCUSSION
Here, we return to Table 1 . The methods can be discussed from three different aspects. The first is whether we can provide the parameter distribution and prediction interval. The methods of the bootstrapping [17] , the cross entropy [19] , the variational Bayes [20] , and the Gaussian process [20] can provide the parameter distribution, and thus the prediction interval as well. The method of the temporal expert advice [11] can provide the prediction interval by weighting predictions according to each expert with Gaussian distributions, although this method cannot provide the parameter distribution itself. The second aspect is whether we use constraints for the parameters. By using constraints for the parameters, we can reproduce relapse under continuous ADT. Although the parametric and semi-parametric estimations can be combined with constraints, and thus reproduce relapse of prostate cancer under continuous ADT, this is not the case for non-parametric estimation.
The third aspect is whether we can use the data of past patients simultaneously with the proposed methods. The methods of the temporal expert advice [11] and the Bayes method with the prior of past patients [12] can be combined with the information of past patients, while the other methods currently cannot. This property is directly linked with how short the time series of the current patient can be. Namely, if we use the data of past patients, we can use a shorter time series to estimate the set of parameters for the current patient.
An important point in the actual clinical setting is whether we can provide multiple indices to make diagnosis and prognosis. Because the methods for parameter estimation discussed here can be used in conjunction with other mathematical models, and other mathematical models for intermittent androgen deprivation therapy of prostate cancer have already been proposed [1, 2, 4, 5] , the use of multiple methods with various models will provide useful information. This is a future direction that we should explore in order to make further progress in mathematical medicine.
